INTRODUCTION: Inhaled @entity842 has been approved by FDA for treatment of @entity1576 in term and near-term neonates. The safety of withdrawing NO in @entity1 who fail to respond is a major concern. OBJECTIVE: To obtain further insight into the safety of withdrawing NO in @entity1 who do not initially respond to this therapy, the charts of @entity1 enrolled at our center in the Neonatal @entity842 Study (NINOS) were reviewed. @entity519 ( @entity519 ) before, during and after exposure to NO or placebo were compared. METHODS: The charts of 110 neonates who received NO or placebo within the NINOS trial guidelines from 1995 to 1999 were reviewed. Arterial blood gases of nonresponders before, during and after a 30-minute exposure to different doses of NO or placebo were analyzed. RESULTS: For both high-dose and 20 ppm nonresponders who received NO, there was no significant change in @entity519 from baseline after withdrawing NO. For @entity1 receiving placebo, there was a significant increase in @entity519 following a 30-minute exposure to placebo. CONCLUSIONS: NO has been shown to be effective in the treatment of @entity1576 ; however, not all recipients demonstrate clinical improvement. This study showed that withdrawing NO in nonresponders did not cause increased @entity1576 when NO exposure was limited to 30 min. Differences between our results and others showing refractory @entity519 after withdrawing NO may be due to different durations of NO exposure and, possibly, its effect on endogenous NO metabolism.

Withdrawal of inhaled XXXX from nonresponders after short exposure.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity519 :: ('MESH:D000860', 'Disease') :: ['Oxygenation indices', 'OI', 'hypoxia'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['Nitric Oxide', 'nitric oxide'] @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory morbidity', 'hypoxic respiratory failure', 'neonatal respiratory failure']
@entity842 :: (MESH:D009569,Chemical) :: ['nitric oxide']
